Accéder au contenu
Merck

Effect of raw Radix Rehmanniae on the pharmacokinetics of pioglitazone in rats.

Pakistan journal of pharmaceutical sciences (2014-05-09)
Zhan Shi, Jingwen Gao, Yuemei Yuan, Shuzhen Zhu, Meicun Yao
RÉSUMÉ

Raw Radix Rehmanniae (RRR) is a frequently used traditional Chinese medicine in the treatment of diabetes mellitus according to the statistics on all of the anti-diabetic formulas recorded in New National Traditional Chinese Medicine. Pioglitazone and RRR may be co-administrated for presumably enhanced therapeutic effects because of the common indications. Therefore, the aim of the study was to evaluate the effect of RRR on the pharmacokinetics of pioglitazone in healthy rats and type 2 diabetic rats. The pharmacokinetic effect of RRR on pioglitazone was studied in healthy rats and type 2 diabetic rats. A validated UPLC-MS/MS method was used to analyze the concentration of pioglitazone in blood samples. The pharmacokinetic parameters were calculated using non-compartmental analyses by Winnonlin 5.0.1. In healthy group, the pre-treatment of RRR significantly (P<0.05) reduced the C(max) but enhanced the V/F of pioglitazone; whereas in T2DM group, significant increase of C(max) and decrease of V/F and T½ were found after the rats were pre-treated with RRR. However, AUC(0-t) and CL/F remained unchanged in both healthy group and T2DM group. In conclusion, co-administration with RRR could alter the pharmacokinetic profiles of pioglitazone to statistically significant levels.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Pioglitazone hydrochloride, ≥98% (HPLC)
USP
Pioglitazone hydrochloride, United States Pharmacopeia (USP) Reference Standard
Pioglitazone hydrochloride, European Pharmacopoeia (EP) Reference Standard
Pioglitazone for system suitability, European Pharmacopoeia (EP) Reference Standard